Resveratrol promotes mitophagy via the MALAT1/miR-143-3p/RRM2 axis and suppresses cancer progression in hepatocellular carcinoma

被引:0
作者
Chunyan Feng [1 ,2 ]
Chengsong Cai [3 ]
Xiaoqian Shi [2 ]
Zhijuan Zhang [1 ]
Dan Su [2 ]
Yunqing Qiu [1 ]
机构
[1] National Key Laboratory of Diagnosis and Treatment of Severe Infectious Disease, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laborato
[2] Department of Clinical Medicine, Hangzhou Medical College
[3] Department of Clinical Laboratory, the Affiliated Hospital of Hangzhou Normal University
关键词
D O I
暂无
中图分类号
R285 [中药药理学];
学科分类号
1008 ;
摘要
Objective: Resveratrol(Res) is a promising anticancer drug against hepatocellular carcinoma(HCC), but whether its anti-HCC effects implicate mitophagy remains unclear. Therefore, we aimed to explore the specific role of Res in mitophagy and the related mechanisms during the treatment of HCC.Methods: Hep G2 cells and tumor-grafted nude mice were used to investigate the effects of low-, middleand high-dose of Res on HCC progression and mitophagy in vitro and in vivo, respectively. A series of approaches including cell counting kit-8, flow cytometry, wound healing and transwell assays were used to evaluate tumor cell functions. Transmission electron microscopy, immunofluorescence and Western blotting were used to assess mitophagy. Mitochondrial oxygen consumption rate, reactive oxygen species and membrane potential were used to reflect mitochondrial function. After disrupting the expression of metastasis-associated lung adenocarcinoma transcript 1(MALAT1), mi R-143-3p, and ribonucleoside reductase M2(RRM2), the effects of the MALAT1/mi R-143-3p/RRM2 axis on cell function and mitophagy under Res treatment were explored in vitro. Additionally, dual-luciferase reporter and chromatin immunoprecipitation were used to confirm interactions between target genes.Results: Res significantly inhibited the proliferation and promoted apoptosis of HCC cells in vitro, while significantly suppressing tumor growth in a dose-dependent manner and inducing mitophagy and mitochondrial dysfunction in vivo. Interestingly, MALAT1 was highly expressed in HCC cells and its knockdown upregulated mi R-143-3p expression in HCC cells, which subsequently inhibited RRM2expression. Furthermore, in nude mice grafted with HCC tumors and treated with Res, the expression of MALAT1, mi R-143-3p and RRM2 were altered significantly. In vitro data further supported the targeted binding relationships between MALAT1 and mi R-143-3p and between mi R-143-3p and RRM2. Therefore,a series of cell-based experiments were carried out to study the mechanism of the MALAT1/mi R-143-3p/RRM2 axis involved in mitophagy and HCC; these experiments revealed that MALAT1 knockdown, mi R-143-3p mimic and RRM silencing potentiated the antitumor effects of Res and its activation of mitophagy.Conclusion: Res facilitated mitophagy in HCC and exerted anti-cancer effects by targeting the MALAT1/mi R-143-3p/RRM2 axis.
引用
收藏
页码:79 / 92
页数:14
相关论文
共 50 条
[41]   A novel mechanism by which ACTA2-AS1 promotes cervical cancer progression: acting as a ceRNA of miR-143-3p to regulate SMAD3 expression [J].
Lingli Luo ;
Min Wang ;
Xianping Li ;
Can Luo ;
Shan Tan ;
Sheng Yin ;
Lei Liu ;
Xiaolin Zhu .
Cancer Cell International, 20
[42]   Induction of lncRNA MALAT1 by hypoxia promotes bone formation by regulating the miR-22-3p/CEBPD axis [J].
Huang, Jiang ;
Shen, Hui-liang ;
Feng, Ming-li ;
Li, Zheng ;
An, Shuai ;
Cao, Guang-lei .
HISTOLOGY AND HISTOPATHOLOGY, 2023, 38 (09) :1043-1053
[43]   A novel mechanism by which ACTA2-AS1 promotes cervical cancer progression: acting as a ceRNA of miR-143-3p to regulate SMAD3 expression [J].
Luo, Lingli ;
Wang, Min ;
Li, Xianping ;
Luo, Can ;
Tan, Shan ;
Yin, Sheng ;
Liu, Lei ;
Zhu, Xiaolin .
CANCER CELL INTERNATIONAL, 2020, 20 (01)
[44]   LINC00460/miR-143-3p/Serpine1 in Promoting Gastric Cancer (GC) Progression [J].
Li, Wulong ;
Yu, Haitao ;
Wei, Dan ;
Ouyang, Gen ;
Li, Ying ;
Tu, Qing .
JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING, 2023, 13 (11) :1082-1093
[45]   MALAT1/mir-1-3p mediated BRF2 expression promotes HCC progression via inhibiting the LKB1/AMPK signaling pathway [J].
Li, Guang-Zhen ;
Meng, Guang-Xiao ;
Pan, Guo-Qiang ;
Zhang, Xiao ;
Yan, Lun-Jie ;
Li, Rui-Zhe ;
Ding, Zi-Niu ;
Tan, Si-Yu ;
Wang, Dong-Xu ;
Tian, Bao-wen ;
Yan, Yu-Chuan ;
Dong, Zhao-Ru ;
Hong, Jian-Guo ;
Li, Tao .
CANCER CELL INTERNATIONAL, 2023, 23 (01)
[46]   Long Noncoding RNA PART1 Promotes Hepatocellular Carcinoma Progression via Targeting miR-590-3p/HMGB2 Axis [J].
Pu, Jian ;
Tan, Chuan ;
Shao, Zesheng ;
Wu, Xianjian ;
Zhang, Ya ;
Xu, Zuoming ;
Wang, Jianchu ;
Tang, Qianli ;
Wei, Huamei .
ONCOTARGETS AND THERAPY, 2020, 13 :9203-9211
[47]   miR-424-3p promotes metastasis of hepatocellular carcinoma via targeting the SRF-STAT1/2 axis [J].
Feng, Lan ;
Chen, Xi ;
Li, Peiyao ;
Li, Yuanfeng ;
Zhai, Yun ;
Liu, Xinyi ;
Jin, Qian ;
Zhang, Hongxing ;
Yu, Chaohui ;
Xing, Baocai ;
Cui, Ying ;
Cao, Pengbo ;
Zhou, Gangqiao .
CARCINOGENESIS, 2023, 44 (07) :610-625
[48]   Retraction Note: Resibufogenin suppresses tumor growth and Warburg effect through regulating miR-143-3p/HK2 axis in breast cancer [J].
Ying Guo ;
Fei Liang ;
Fuli Zhao ;
Jian Zhao .
Molecular and Cellular Biochemistry, 2022, 477 :2687-2687
[49]   MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p [J].
Liu, Ke ;
Huang, Jun ;
Ni, Jiangdong ;
Song, Deye ;
Ding, Muliang ;
Wang, Junjie ;
Huang, Xianzhe ;
Li, Wenzhao .
CELL CYCLE, 2017, 16 (06) :578-587
[50]   Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma [J].
Nie, Huizhen ;
Li, Jun ;
Yang, Xiao-Mei ;
Cao, Qing-Zhen ;
Feng, Ming-Xuan ;
Xue, Feng ;
Wei, Lin ;
Qin, Wenxin ;
Gu, Jianren ;
Xia, Qiang ;
Zhang, Zhi-Gang .
HEPATOLOGY, 2015, 62 (04) :1145-1159